

Clinical Trial Protocol

Iranian Registry of Clinical Trials

08 Jul 2026

Comparison of the effectiveness and side effects of ketamine and haloperidol in controlling acute delirium and acute agitation

Protocol summary

agitation based on Richmond Agitation Sedation Score

Study aim

Comparison of the effectiveness and side effects of ketamine vs haloperidol for acute control of agitation

Design

This is a phase-3 clinical trial study, two arms parallel group randomized with blinded post-treatment and outcome assessment.

Settings and conduct

This study will be conducted on all patients over 18 years with acute agitation who refer to the emergency department of Qaem, Imam Reza, and Hashemi Nezaad hospitals in Mashhad. Herein, patients are divided into two groups based on a table of random numbers, and the name of the prescribed drug is placed inside an envelope in a package. The colleague nurse opens the envelope, prescribes the drug, and then writes the number of the envelope on a checklist which is later completed by the emergency medicine assistant. Then the medical assistant will evaluate the patient and at the end, the envelopes are opened and the prescribed drug for each patient is determined and the data is analyzed. The researcher and medical assistant are blinded in this study.

Participants/Inclusion and exclusion criteria

All agitated patients, after being evaluated for treatable causes such as hypoxia and hypoglycemia are enrolled in this study. Patients with a history of sensitivity to these drugs, any past medical history of dissection or cardiac infarction and QT prolongation, are excluded from the study.

Intervention groups

In this study all patients with acute agitation which is not related to treatable causes are enrolled.

Main outcome variables

- 1- Determine and compare the side effects of two drugs
- 2- Determine and compare the time required until the patient's sedation after receiving ketamine and haloperidol
- 3- Determine and compare the effectiveness of ketamine and haloperidol in controlling patient

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20230612058465N1**

Registration date: **2023-06-18, 1402/03/28**

Registration timing: **prospective**

Last update: **2023-06-18, 1402/03/28**

Update count: **0**

Registration date

2023-06-18, 1402/03/28

Registrant information

Name

Islamic Republic of Iran Vafadar moradi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 51 3852 5312

Email address

vafadarme@mums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-06-28, 1402/04/07

Expected recruitment end date

2024-06-27, 1403/04/07

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of the effectiveness and side effects of ketamine and haloperidol in controlling acute delirium and acute agitation

Public title

Ketamine effectiveness for acute agitation

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

All acutely agitated patients enrolled in the study. Treatable causes such as hypoxia and hypoglycemia were evaluated in if present, treated.

Exclusion criteria:

Any sensitivity to ketamine or haloperidol, past medical history of dissection or myocardial infarction, or QT prolongation lead to exclude from the study.

Age

From **18 years** old to **85 years** old

Gender

Both

Phase

3

Groups that have been masked

- Investigator
- Outcome assessor

Sample size

Target sample size: **120**

More than 1 sample in each individual

Number of samples in each individual: **60**

Sixty

Randomization (investigator's opinion)

Randomized

Randomization description

Patients are divided into two groups based on a table of random numbers, and the name of the prescribed drug is placed inside an envelope in a package. The colleague nurse opens the envelope, prescribes the drug, and then writes the number of the envelope on a checklist which is later completed by the emergency medicine assistant. Then the medical assistant will evaluate the patient and at the end, the envelopes are opened and the prescribed drug for each patient is determined and the data is analyzed. The researcher and medical assistant are blinded in this study.

Blinding (investigator's opinion)

Double blinded

Blinding description

In this study, the researcher and the assessor, who is an emergency medicine assistant, are blinded to the drug prescribed by the nurse colleague in the study. At first, based on the table of random numbers, the number and type of prescribed drug is placed in an envelope, the colleague nurse administer the drug without the researcher's accompaniment and records the number of the envelope in the checklist, then the medical assistant evaluated the patient. Finally, after the end of the study, the envelopes are opened and the prescription drug in

each checklist is determined and the data are analyzed.

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Research Ethic committee of Imam Reza Hospital, Research and Treatment center-Mashhad University of

Street address

Razi squ.

City

Mashhad

Province

Razavi Khorasan

Postal code

9137913316

Approval date

2023-05-01, 1402/02/11

Ethics committee reference number

IR.MUMS.IRH.REC.1402.062

Health conditions studied

1

Description of health condition studied

Acute agitation

ICD-10 code

agitation

ICD-10 code description

Restlessness and agitation

Primary outcomes

1

Description

Agitation control based on RASS score

Timepoint

After admission, 30 and 60 minutes after the drug administration

Method of measurement

Agitation control will be assess by Richmond Agitation and Sedation Score.

Secondary outcomes

1

Description

The sedation time based on minutes, the side effects of drugs include apnea, nausea and vomiting, need for intubation, tachycardia, hypertension, tachycardia, QT prolongation, tachycardia, and dysrhythmias.

Timepoint

At admission and 30 and 60 minutes after drug administration

Method of measurement

Any side effects and time to sedation(minutes) will document.

Intervention groups

1

Description

Intervention group: Ketamine Group

Category

Treatment - Drugs

2

Description

Intervention group: Haloperidol group

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Ghaem hospital, Emam Reza hospital, Shahid Hasheminejad hospital

Full name of responsible person

Ala Montazeri

Street address

Ahmad abad blov., Razi Squ., Abureihan blov.

City

Mashhad

Province

Razavi Khorasan

Postal code

۹۱۳۷۹۱۳۳۱۶

Phone

+98 51 3852 5312

Fax

+98 51 3852 5312

Email

Ala.montazeri@gmail.com

Web page address

<https://emamreza.mums.ac.ir/>

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Majid Ghayour moborhan

Street address

Daneshgah Street, next to Hoizeh Cinema, University of Medical Sciences, 3rd floor, University Research and Technology Vice-Chancellor

City

Mashhad

Province

Razavi Khorasan

Postal code

9138813944

Phone

+98 51 3841 1538

Fax

+98 51 3843 0249

Email

vcresraech@mums.ac.ir

Web page address

<https://v-research.mums.ac.ir>

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Mashhad University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Elnaz Vafadar Moradi

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Emergency Medicine

Street address

Razi squ.

City

Mashhad

Province

Razavi Khorasan

Postal code

۹۱۳۷۹۱۳۳۱۶

Phone
+98 51 3852 5312
Email
VafadarME@mums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Elnaz Vafadar Moradi
Position
Assistant Professor
Latest degree
Specialist
Other areas of specialty/work
Emergency Medicine
Street address
Razi squ.
City
Mashhad
Province
Razavi Khorasan
Postal code
9137913316
Phone
+98 51 3852 5312
Email
Vafadarme@mums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Ala Montazeri
Position
Emergency resident
Latest degree
Medical doctor
Other areas of specialty/work
Emergency Medicine
Street address

Razi squ.
City
Mashhad
Province
Razavi Khorasan
Postal code
9137913316
Phone
+98 51 3852 5312
Email
Ala.montazeri@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

All data can be shared after the completion of the study and after the approval of the ethics committee of the university.

When the data will become available and for how long

immediately after acceptance of the manuscript.

To whom data/document is available

All researchers of academic centers.

Under which criteria data/document could be used

For further investigation

From where data/document is obtainable

Elnaz Vafadar Moradi MD.

What processes are involved for a request to access data/document

You can E-mail me and tell me the reason for requesting the data, I will send to request to ethics committee, and if they approved, I will send the data.

Comments